A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
AstraZeneca
AbbVie
National Institutes of Health Clinical Center (CC)
University of Utah
Syndax Pharmaceuticals
Daiichi Sankyo
Albert Einstein College of Medicine
Merck Sharp & Dohme LLC
Celgene
AbbVie
GlaxoSmithKline
Hoffmann-La Roche
Hoffmann-La Roche
Progen Pharmaceuticals
Eli Lilly and Company
Regeneron Pharmaceuticals
PharmaMar
AVEO Pharmaceuticals, Inc.
Alaunos Therapeutics
Sanofi
Sanofi
Astellas Pharma Inc